QR Kodea

Efficacy of Osimertinib in Patients With Postoperative Recurrent Non–Small‐Cell Lung Cancer Harboring Sensitizing EGFR Mutations

ABSTRACT Background The efficacy of osimertinib in patients with postoperative recurrent non–small‐cell lung cancer (NSCLC) compared to those with Stage IV NSCLC harboring epidermal growth factor receptor (EGFR) mutations remains unclear. Methods This study evaluated the efficacy of osimertinib in p...

Deskribapen osoa

Gorde:
Egile Nagusiak: Yuko Iida, Hirotsugu Kenmotsu, Keita Mori, Meiko Morita, Motoki Sekikawa, Michitoshi Yabe, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Yasuhisa Ohde, Yasuhiro Gon, Toshiaki Takahashi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Wiley 2026-04-01
Saila:Thoracic Cancer
Gaiak:
EGFR
mutation
non–small‐cell lung cancer
osimertinib
postoperative recurrent
Sarrera elektronikoa:https://doi.org/10.1111/1759-7714.70285
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak